newsfilter
← Latest News
GlobeNewswire·

Bright Minds Biosciences ("BMB") Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity

-- BMB proprietary 5-HT2C agonist, BMB-101, shows efficacy in pre-clinical models of Dravet Syndrome/Epilepsy, with lower seizure duration and frequency -- -- Effect of BMB compounds was consistent with other anti-epileptics such as fenfluramine